AN EXPANDED ACCESS STUDY OF PALBOCICLIB IN COMBINATION WITH LETROZOLE AS TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE ADVANCED BREAST CANCER FOR WHOM LETROZOLE THERAPY IS DEEMED APPROPRIATE
AN EXPANDED ACCESS STUDY OF PALBOCICLIB IN COMBINATION WITH LETROZOLE AS TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE ADVANCED BREAST CANCER FOR WHOM LETROZOLE THERAPY IS DEEMED APPROPRIATE
To provide access to palbociclib to post-menopausal women with HR-positive, HER2-negative advanced breast cancer who are deemed appropriate for letrozole therapy (Canada: first-line patients only).
This study is currently available in Canada only.
Inclusion Criteria:
Exclusion Criteria:
Bakersfield, California 93309, United States
Washington D.C., District of Columbia 20010, United States
Duluth, Georgia 30096, United States
Lawrenceville, Georgia 30046, United States
Baltimore, Maryland 21287, United States
Pittsburgh, Pennsylvania 15232, United States
Pittsburgh, Pennsylvania 15232, United States
Fairfax, Virginia 22031, United States
Reston, Virginia 20190, United States
Halifax, Nova Scotia B3H 1V7, Canada
Montreal, Quebec H4A 3J1, Canada